Compare
Collegium Pharmaceutical, Inc vs Emergent BioSolutions Inc. vs Pacira BioSciences, Inc. vs Amphastar Pharmaceuticals, Inc.
| Latest fiscal year | Collegium Pharmaceutical, Inc COLL | Emergent BioSolutions Inc. EBS | Pacira BioSciences, Inc. PCRX | Amphastar Pharmaceuticals, Inc. AMPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $780.57M | $742.90M | $726.41M | $719.89M |
| Revenue growth (YoY) | +23.6% | -28.8% | +3.6% | -1.7% |
| Gross margin | 59.3% | 56.1% (computed) | 79.4% (computed) | 49.5% |
| Operating margin | 23.0% | 13.5% | 2.6% | 19.5% |
| Net margin | 8.1% | 7.1% | 1.0% | 13.6% |
| Net income | $62.87M | $52.60M | $7.03M | $98.09M |
| EPS (Diluted) | $1.73 | $0.93 | $0.16 | $2.03 |
| Operating cash flow | $329.32M | $170.60M | $151.99M | $156.12M |
| Free cash flow | $327.58M | $156.80M | $136.66M | $121.23M |
| Cash & equivalents | $231.25M | $205.40M | $158.54M | $170.18M |
| Total assets | $1.66B | $1.32B | $1.26B | $1.63B |
| Total liabilities | $1.36B | $796.00M | $571.81M | $840.49M |
| Shareholders' equity | $301.68M | $522.60M | $693.11M | $788.80M |
| Return on year-end equity | 20.8% | 10.1% | 1.0% | 12.4% |
| Shares outstanding | 31.71M | 52.10M | 41.12M | 45.65M |
Revenue, most recent five fiscal years
| Fiscal year | Collegium Pharmaceutical, Inc | Emergent BioSolutions Inc. | Pacira BioSciences, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $780.57M Ended 2025-12-31 | $742.90M Ended 2025-12-31 | $726.41M Ended 2025-12-31 | $719.89M Ended 2025-12-31 |
| 1 year earlier | $631.45M Ended 2024-12-31 | $1.04B Ended 2024-12-31 | $700.97M Ended 2024-12-31 | $731.97M Ended 2024-12-31 |
| 2 years earlier | $566.77M Ended 2023-12-31 | $1.05B Ended 2023-12-31 | $674.98M Ended 2023-12-31 | $644.39M Ended 2023-12-31 |
| 3 years earlier | $463.93M Ended 2022-12-31 | $1.12B Ended 2022-12-31 | $666.82M Ended 2022-12-31 | $498.99M Ended 2022-12-31 |
| 4 years earlier | $276.87M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $541.53M Ended 2021-12-31 | $437.77M Ended 2021-12-31 |